BRIEF—PharmaMar licenses Zepsyre to Boryung Pharm in Korea

Spanish drugmaker PharmaMar has signed a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre (lurbinectedin), if approved, in South Korea.

Under the terms of the agreement, PharmaMar receives a non-disclosed upfront payment and will be eligible for additional remunerations upon achieving regulatory and sales milestones.

PharmaMar will retain exclusive production rights and will sell the product to Boryung Pharm for commercial use, if approved.

Zepsyre is currently in late-stage clinical development for platinum-resistant ovarian cancer and for small-cell lung cancer.

After results obtained in clinical trials about BRCA 2-associated metastatic breast cancer and endometrial cancer, PharmaMar also plans to initiate a pivotal Phase III study in each of those indications.